A citation-based method for searching scientific literature

Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
Times Cited: 258



Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
Times Cited: 1124




List of shared articles



Times cited

A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing.
Sounak Gupta, Chad M Vanderbilt, Yun-Te Lin, Jamal K Benhamida, Achim A Jungbluth, Satshil Rana, Amir Momeni-Boroujeni, Jason C Chang, Tiffany Mcfarlane, Paulo Salazar,[...]. J Mol Diagn 2021
3

Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations.
Peng-Cheng Yu, Li-Cheng Tan, Xiao-Li Zhu, Xiao Shi, Roman Chernikov, Arseny Semenov, Ling Zhang, Ben Ma, Yu Wang, Xiao-Yan Zhou,[...]. Endocr Pract 2021
2

TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients.
Jun Park, Sungjoo Lee, Kyunga Kim, Hyunju Park, Chang-Seok Ki, Young Lyun Oh, Jung Hee Shin, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung,[...]. Cancers (Basel) 2021
4

Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.
Jinwei Hu, Isabella J Yuan, Saied Mirshahidi, Alfred Simental, Steve C Lee, Xiangpeng Yuan. Int J Mol Sci 2021
2

Molecular pathogenesis of pediatric thyroid carcinoma.
Norisato Mitsutake, Vladimir Saenko. J Radiat Res 2021
1

Nuclear-specific accumulation of telomerase reverse transcriptase (TERT) mRNA in TERT promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool?
L Samuel Hellgren, Ann Olsson, Ann Kaufeldt, Johan O Paulsson, Martin Hysek, Adam Stenman, Jan Zedenius, Catharina Larsson, Anders Höög, C Christofer Juhlin. J Clin Pathol 2021
0

Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma.
Yujiro Hayashi, Kazutoshi Fujita, George J Netto, Norio Nonomura. Front Oncol 2021
0

Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations.
Hyunju Park, Hyeong Chan Shin, Heera Yang, Jung Heo, Chang-Seok Ki, Hye Seung Kim, Jung-Han Kim, Soo Yeon Hahn, Yun Jae Chung, Sun Wook Kim,[...]. Mod Pathol 2021
0

Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
Marilena Argyropoulou, Aristidis S Veskoukis, Pagona-Maria Karanatsiou, Aikaterini Manolakelli, Ifigenia Kostoglou-Athanassiou, George Vilaras, Andreas Karameris, Kalliopi Liadaki. Pathol Oncol Res 2020
9



Clinical and Translational Challenges in Thyroid Cancer.
Jorge Hernando, Javier Ros, Alvaro Arroyo, Jaume Capdevila. Curr Med Chem 2020
3

The Solo Play of TERT Promoter Mutations.
François Hafezi, Danielle Perez Bercoff. Cells 2020
8

Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Balakrishna Koneru, Gonzalo Lopez, Ahsan Farooqi, Karina L Conkrite, Thinh H Nguyen, Shawn J Macha, Apexa Modi, Jo Lynne Rokita, Eduardo Urias, Ashly Hindle,[...]. Cancer Res 2020
14


Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans.
Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung. J Pathol Transl Med 2020
7

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma.
Dagmara Rusinek, Aleksandra Pfeifer, Marta Cieslicka, Malgorzata Kowalska, Agnieszka Pawlaczek, Jolanta Krajewska, Sylwia Szpak-Ulczok, Tomasz Tyszkiewicz, Monika Halczok, Agnieszka Czarniecka,[...]. Cancers (Basel) 2020
6

Comprehensive Assessment of TERT mRNA Expression across a Large Cohort of Benign and Malignant Thyroid Tumours.
Ana Pestana, Rui Batista, Ricardo Celestino, Sule Canberk, Manuel Sobrinho-Simões, Paula Soares. Cancers (Basel) 2020
4

Telomeres and Telomerase in the Development of Liver Cancer.
Lena In der Stroth, Umesh Tharehalli, Cagatay Günes, André Lechel. Cancers (Basel) 2020
10

Implications of telomerase reverse transcriptase in tumor metastasis.
Yongkang Zou, Yu-Sheng Cong, Junzhi Zhou. BMB Rep 2020
0

Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.
Marta Dratwa, Barbara Wysoczanska, Eliza Turlej, Artur Anisiewicz, Magdalena Maciejewska, Joanna Wietrzyk, Katarzyna Bogunia-Kubik. Exp Cell Res 2020
2

Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.
Naoki Oishi, Huy Gia Vuong, Kunio Mochizuki, Tetsuo Kondo. Endocr Pathol 2020
2


GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Xiaotian Yuan, Ninni Mu, Na Wang, Klas Strååt, Anastasios Sofiadis, Yanxia Guo, Adam Stenman, Kailin Li, Guanghui Cheng, Lu Zhang,[...]. Oncogene 2019
21

TERT gene: its function and dysregulation in cancer.
Andrew J Colebatch, Alexander Dobrovic, Wendy A Cooper. J Clin Pathol 2019
19

Genetic-guided Risk Assessment and Management of Thyroid Cancer.
Mingzhao Xing. Endocrinol Metab Clin North Am 2019
18

Coding Molecular Determinants of Thyroid Cancer Development and Progression.
Veronica Valvo, Carmelo Nucera. Endocrinol Metab Clin North Am 2019
7

Genomics-Enabled Precision Medicine for Cancer.
Alison Roos, Sara A Byron. Cancer Treat Res 2019
3

TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas.
Aya Tanaka, Michiko Matsuse, Vladimir Saenko, Tomoe Nakao, Kosho Yamanouchi, Chika Sakimura, Hiroshi Yano, Eijun Nishihara, Mitsuyoshi Hirokawa, Keiji Suzuki,[...]. Thyroid 2019
17

Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Federica Panebianco, Alyaksandr V Nikitski, Marina N Nikiforova, Yuri E Nikiforov. Cancer Med 2019
17

Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor.
Sevim Dalva-Aydemir, Cemaliye Boylu Akyerli, Şirin Kılıçturgay Yüksel, Hilal Keskin, Mustafa Cengiz Yakıcıer. OMICS 2019
3

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Rong Bu, Abdul K Siraj, Sasidharan Padmaja Divya, Yan Kong, Sandeep Kumar Parvathareddy, Maha Al-Rasheed, Khadija A S Al-Obaisi, Ingrid G Victoria, Saif S Al-Sobhi, Mohammed Al-Dawish,[...]. Int J Cancer 2018
31

Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.
Henrik Hornshøj, Morten Muhlig Nielsen, Nicholas A Sinnott-Armstrong, Michał P Świtnicki, Malene Juul, Tobias Madsen, Richard Sallari, Manolis Kellis, Torben Ørntoft, Asger Hobolth,[...]. NPJ Genom Med 2018
31